Table 2. In vivo administration of Nutlin‐3 selectively affects the tumorigenicity and CSC content of Numb tumors, but not of Numb+ tumors
TumorTreatmentNr. of cells injectedFreq. SCs/CICs95% CIP‐value
1051045 × 103103102101
Outgrowths/injections
Numb tumorsT1Ctr2/22/24/61/80/20/21:4,6601:2,147–1:10,1150.005
T1Nut.2/23/81/80/80/20/21:26,2841:10,794–1:64,008
T2Ctr2/22/23/61/62/80/21:4,2021:1,928–1:9,1570.002
T2Nut.2/24/101/80/80/20/21:24,2001:10,660–1:54,939
T3Ctr2/24/44/60/60/20/21:4,7431:2,286–1:9,8420.002
T3Nut.2/22/81/70/20/20/21:31,7311:12,082–1:83,335
T4Ctr2/24/42/41/60/20/21:4,7581:2,140–1:10,5800.003
T4Nut.2/23/80/80/20/20/21:32,3191:12,467–1:83,786
Numb+ tumorsTCCtr2/26/63/80/80/20/21:6,9911:3,621–1:13,4980.688
TCNut.2/26/63/60/80/20/21:5,6981:2,907–1:11,172
TDCtr2/24/43/61/80/20/21:5,4031:2,618–1:11,1510.770
TDNut.2/24/43/62/80/20/21:4,6301:2,277–1:9,414
  • Limiting dilution orthotopic re‐transplantation of explanted cells from the indicated tumors treated in vivo with Nutlin‐3 (Nut.) or vehicle DMSO (Ctr) as in Fig 6A. The complete statistical analysis of the experiment, with the frequency of CICs and with 95% confidence intervals (CI), is shown. Analyses were performed as described in the legend to Table 1.